Stifel Downgrades Silk Road Medical to Hold, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Rick Wise has downgraded Silk Road Medical (NASDAQ:SILK) from Buy to Hold and lowered the price target from $45 to $12.

October 11, 2023 | 10:00 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Silk Road Medical's stock rating has been downgraded from Buy to Hold by Stifel, with a significant reduction in price target from $45 to $12.
The downgrade from Buy to Hold indicates a less optimistic outlook for the company's stock. The significant reduction in price target from $45 to $12 suggests that the analyst expects the stock price to decrease in the short term. This could potentially lead to a sell-off, negatively impacting the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100